Therefore, in the present study, the role and applications of Gal-3 as a diagnostic, prognostic, and risk stratifying biomarker in heart disease and cancer, as well as therapeutic approach, were investigated with special emphasis to prostate cancer (PCa). This evidence concerns the gene LGALS3 and Familial prostate cancer.